How do you utilize anifrolumab for SLE in your practice?
This question is part of a collaboration with RheumMadness and is specifically in reference to: Long-term outcomes of anifrolumab in SLE.
Community PollStarted
When do you consider use of anifrolumab in patients with non-renal manifestations of SLE?
168 physicians have voted
Join Mednetto vote and see how they answered.
2 Answers
Mednet MemberInvited Expert
Rheumatology · Uniformed Services University of the Health Sciences (USUHS)
Answered on · Updated on
The answer to this SLE question involves a complex decision-making process. It is such an important question! I apologize in advance for the long answer.
I am in the camp of achieving remission in my SLE patients and getting them off prednisone in the safest ways possible (Fanouriakis et al., PMID 3...
Join for free or sign in to see the full answer
Mednet MemberInvited Expert
Rheumatology · MedStar Georgetown University Hospital
Answered on · Updated on
I think of anifrolumab particularly for patients with cutaneous disease. The TULIP-2 trial showed promise for anifrolumab in these patients as a secondary endpoint. In patients with at least moderately active skin disease, 49% of patients achieved >= 50% reduction in CLASI compared to 25% in the pla...
Join for free or sign in to see the full answer